Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion

Siehste ja - schön 🥳

Hi, wie sind denn hier die Aussichten ?

👀

😎

👀

Wird nicht lange dauern. Kaufen würde ich hier trotzdem nix mehr außer es gibt was positives zu berichten.

Bei 0,10 lege ich nochmal nach

Denk auch..liegen lassen

Hier ist für lange Zeit der Saft raus...

Na ja, wie gewonnen so zerronnen 🤷‍♂️

👀

Gut 👍 weiter so

Kommt ja wieder 😊

“Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development. Expanding the number of sites may accelerate enrollment. We anticipate seeing preliminary results from this study in the first half of 2023."

Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML Additional Clinical Sites Expected to Enroll CMML Patients in Australia

https://www.newsfilecorp.com/release/136537/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACHM-Study-of-Lenzilumab-in-CMML